An ever-expanding portfolio of promising new compounds.
Daiichi Sankyo is dedicated to the innovative development and commercialization of pharmaceutical products that address diversified, unmet medical needs in mature and emerging markets.
Our commitment to the discovery, development and delivery of innovative medicines dates back more than a century ago, when Daiichi Sankyo scientists first discovered epinephrine (also known as adrenaline). Our passion for innovation continued and led to the isolation of B vitamins, the development of the first statin (a class of medications used to treat high cholesterol) and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes.
Today, we bring this same dedication and drive to our pipeline of compounds. Everyday, our scientists focus on streamlining the journey from discovery to approval of new compounds with enormous therapeutic potential. Whether focusing on our portfolio of medicines to treat cardiovascular and metabolic diseases or expanding our pipeline of oncology therapies, Daiichi Sankyo is committed to creating first-in-class and best-in-class therapies.
|Therapeutic Area ||PHASE 1 ||PHASE 2 ||PHASE 3 ||APPLICATION |
|Cardiovascular-Metabolic || || || |
- Prasugrel (JP) (ischemic stroke)
- Prasugrel (US) (Sickle Cell Disease)
- CS-747 Prasugrel (JP) (PCI)
|Oncology || || |
- U3-1287 (US/EU) patritumab
- PLX4032 (US/EU) vemurafenib
- AMG 162 (JP) denosumab (breast cancer adjuvant)
- DE-766 (JP) nimotuzumab (NSCLC)
- DE-766 (JP) nimotuzumab (Gastric Cancer)
- AMG 162 (JP) denosumab (GCT of bone)
|OTHER || || || |
- DR-3355 (JP) levofloxacin
- AMG 162 (JP) denosumab (rheumatoid arthritis)
The most advanced stages are described here in oncology area
#: Study on-going outside Japan
Note: These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation.
As of 1.31.2014